

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Pomalidomide in combination with bortezomib and
dexamethasone for treating relapsed or refractory multiple
myeloma ID1358**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues were identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of pomalidomide in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1358]

Issue date: October 2018

1 of 2

N/A

Approved by Associate Director (name): ...Melinda Goodall.....

Date: 13/09/2018